Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Alice Kacuba, RN, MSN

Advertisement

Articles by Alice Kacuba, RN, MSN

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

ByGeorge Shashaty, MD,Raymond Frankewich, PhD,Tamal Chakraborti, PhD,Jasti Choudary, PhD,Suliman Al-fayoumi, PhD,Alice Kacuba, RN, MSN,Sonia Castillo, PhD,Kathy Robie-suh, MD, PhD,Dwaine Rieves, MD,Karen Weiss, MD,Richard Pazdur, MD
December 1st 2006

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.

Advertisement

Latest Updated Articles

  • Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis
    Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

    December 1st 2006



Advertisement
Advertisement

Trending on CancerNetwork

1

ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma

2

What Are The Top Lymphoma Abstracts at ASCO 2026?

3

ASCO 2026: Key Genitourinary Oncology Trials to Watch For

4

Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC

5

How the Landscape of GI Oncology is Evolving: A 2026 ASCO Preview

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us